Obesity market sales potential tightens as Novo and Lilly enter new era

Core Viewpoint - The expectation that the global market for obesity drugs would reach $150 billion in the next decade is becoming uncertain due to falling prices for GLP-1 treatments in the U.S. [1] Group 1: Market Expectations - Wall Street's long-held expectation for the obesity drug market is now in question [1] - The anticipated market size of $150 billion may not be achievable as previously thought [1] Group 2: Pricing Trends - U.S. prices for GLP-1 treatments are experiencing a decline [1] - The price drop could significantly impact revenue projections for companies involved in obesity drug development [1]